Changeflow GovPing Pharma & Drug Safety Opioid Overdose Prevention Formulations - Indiv...
Routine Notice Added Final

Opioid Overdose Prevention Formulations - Indivior Inc.

Favicon for changeflow.com EPO Patent Bulletin - Therapeutics (A61P)
Published
Detected
Email

Summary

The European Patent Office published patent application EP3793558A1 for Indivior Inc., covering formulations and methods for preventing opioid overdose using intranasal drug delivery. The patent application designates 35 European states including major markets. This patent grants Indivior exclusive rights to its opioid overdose prevention technology in European markets.

What changed

The European Patent Office published patent application EP3793558A1 for Indivior Inc. covering pharmaceutical formulations for opioid overdose prevention. The patent includes claims related to intranasal drug delivery systems (A61M classifications) and specific compound formulations (A61K 31/485). The application designates 35 European contracting states for patent protection.

Pharmaceutical companies and drug manufacturers developing opioid reversal agents or similar overdose prevention products should review this patent to assess potential freedom-to-operate concerns in European markets. Generic drug manufacturers and generic naloxone producers may need to evaluate whether their products fall within the scope of these claims.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 10, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

FORMULATIONS AND METHODS FOR THE PREVENTION OF OPIOID OVERDOSE

Publication EP3793558A1 Kind: A1 Apr 01, 2026

Applicants

Indivior Inc.

Inventors

CRYSTAL, Roger, SKOLNICK, Phil, MAGGIO, Edward, T.

IPC Classifications

A61K 31/485 20060101AFI20220318BHEP A61K 9/00 20060101ALI20220318BHEP A61M 11/00 20060101ALI20220318BHEP A61K 47/02 20060101ALI20220318BHEP A61K 47/18 20170101ALI20220318BHEP A61P 25/36 20060101ALI20220318BHEP A61P 43/00 20060101ALI20220318BHEP A61M 15/08 20060101ALI20220318BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3793558A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application IP licensing
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!